SEC Tracker
Get the app

PMV Pharmaceuticals PMVP

PMV Pharmaceuticals reports Q3 2026 results and corporate updates

PMV Pharmaceuticals (PMVP) filed an 8-K with the SEC on Nov 10, 2026, 8:00 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash, cash equivalents, and marketable securities of $108.5 million as of September 30, 2026
  2. Net loss for the quarter ended September 30, 2026, was $34.4 million
  3. Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in Q1 2027
  4. Announced closing of oversubscribed $50 million public offering

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when PMV Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.